Buradasınız

Anasayfa » Content

Renal Transplant Alıcılarınd a Hiperkolesterolemi Tedavisi

Treatment of Hypercholesterolemia in the Kidney Transplant Recipient Population

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2006

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The prevalence of dyslipidemias in kidney transplant recipients is very high particularly common as increases in total cholesterol and low density lipoprotein. Hyperlipidemia contribute to the risk of premature atherosclerosis and cardiovascular death in these pati¬ents. Kidney transplant patients should be considered to be in the highest risk category for atherosclerotic coronary heart disease and evaluation of dyslipidemia should occur for kidney transplant recipient population at presentation, after a change in status and annually. Beneficial effects of statins specific to the kidney transplant popula¬tion that have been demonstrated previously include favorable ef¬fects on cardiac events, acute rejection, associations with improved patient survival, lower blood pressure, and improved bone mineral density. In this review, the treatment strategy of hyperlipidemia in kidney transplant recipient population will be discussed.
Bookmark/Search this post with
Abstract (Original Language): 
Renal transplant alıcılarında , dislipidemi prevalansı (özellikle total kolesterol ve düşük dansiteli lipoprotein artışı olarak) oldukça yüksek bulunmaktadır. Bu hastalarda hiperlipidemi varlığı, ate-roskleroz ve kardiyovasküler ölüm riskine katkıda bulunmaktadır. Aterosklerotik koroner arter hastalığı için renal transplant alıcıları, en yüksek risk grubunda olup, dislipidemi değerlendirmesi başlangıçta, durumda bir değişiklik olduğunda ve yıllık olarak yapılmalıdır. Renal transplant alıcılarında statin tedavisinin yararları, kardi-yak olaylarda, akut rejeksiyonda, kan basıncı kontrolünde, kemik mineral dansitesi ve sağkalımda düzelmede gösterilmiştir. Bu der¬lemede, renal transplant alıcılarında hiperlipidemiyle ilgili tedavi stratejileri tartışılacaktır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_620.pdf
  • 4
186-100
  • Turkish

REFERENCES

References: 

1. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001;16:1545-9.
2. Kasiske BL. Cardiovascular disease after renal transplantation. Semin Nephrol 2000;20:176-87.
3. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease- major cause of de¬ath and graft loss after renal transplantation in Scandinavia.
Transplantation 1995;60:451-7.
4. Kendrick E. Cardiovascular disease and the renal transplant
recipient. Am J Kidney Dis 2001;38:36-43.
5. Guijarro C, Massy ZA, Kasiske BL. Clinical correlation between renal allograft failure and hyperlipidemia. Kidney Int
1995;52:56-9.
6. Dimeny E, Wahlberg J, Lithell H, Fellstrom B. Hyperlipidemia in renal transplantation- risk factor for long-term graft outco¬me. Eur J Clin Invest 1995;25:574-83.
7. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholes-terolemia. Am J Kidney Dis 1991;18:353-8.
8. Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage re¬nal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc
Nephrol 1998;9:2135-2141.
9. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIn-tosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Eng J
Med 2000;342:605-612.
10. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232;34-47.
11. Leung WH, Lau CP, Wong CK. Beneficial effect of choleste¬rol lowering therapy on coronary endothelium-dependent re¬laxation in hypercholesterolemic patients. Lancet
1993;341:1496-1500.
12. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotro-pic effects of statins: Lipid reduction and beyond. J Clin En-
docrin Metab 2002;87:1451-1458.
13. Wheeler DC. Lipids-what is the evidence for their role in progressive renal disease? Nephrol Dial Transplant
1995;10:14-6.
14. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J et al. Effects of 3-H-3-MG-CoA reductase inhibitors, atorvastatin and simvastatin on the expression of endothelin-1 and endot-helia nitric oxide synthase in vascular endothelial cells. J Clin
Invest 1998;101:2711-9.
15. Kaesemeyer WH, Kaldwell RB, Huang J, Caldwell RW. Pra-
vastatin sodium activates nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol
1999;33:234-41.
16. Gogers MJ. Statins: lower lipids and beter bones? Nature Me¬dicine 2000;6:21-3.
Official Journal of the Turkish Society of Nephrology / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
189
9 Treatment of Hypercholesterolemia in the Kidney Transplant Recipient Population
17. Harst PVD, Voors AA, Gilst WHV, Böhm M, Veldhuisen DJV. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiores 2006; in press.
18. Liu J and Rosner MH. Lipid abnormalities associated with end-stage renal disease. Endocrinology and dialysis
2006;19:32-40.
19. Kasiske BL. Hyperlipidemia in patients with chronic renal di¬sease. Am J Kidney Dis 1998;32:142-156.
20. Kasiske BL, Vazquez MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 2000;11:1-86.
21. Drueke TB, Abdulmassih Z, Lacour B, Bader C, Chevalier A, Kreis H. Atherosclerosis and lipid disorders after renal transplantation. Kidney Int 1991;31:24-28.
22. Kasiske BL. Cardiovascular disease after renal transplantation. Semin Nephrol 2000;20:170-187.
23. Pearson TA, McBride PE, Miller NH, Smith SC. 27th Bethesda Conference, Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 1996;27:1039-1047.
24. Agarwal R. Effects of statins on renal function. Am J Cardiol
2006;97:748-755.
25. Schaeffner ES, Fodinger M, Kramar R, Frei U, Horl WH, Sun-der-Plassmann G, Winkelmayer WC. Prognostic associations between lipid markers and outcomes in kidney transplant recipients. Am J Kidney Dis 2006;47:509-17.
26. Holdaas H, Fellström B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomized, placebo controlled trial. Lancet
2003;361:2024-2031.
27. Holdaas H, Jardine AG, Wheeler DC et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicen-ter trial. Kidney Int 2001;60:1990-1997.
28. Kobashigawa J, Kasiske B. Hyperlipidemia in solid organ transplantation. Transplantation 1997;63:331-338.
29. Holdaas H, Fellström B, Jardine AG, Nyberg G et al. Benefi¬cial effect of early initiation of lipid-lowering therapy follo¬wing renal transplantation. Nephrol Dial Transplant
2005;20:974-980.
30. Kasiske B, Cosio FG, Beto J et al. Clinical Practice Guidelines for Managing Dyslipidemias in Kidney Transplant Patients: A report from the managing Dyslipidemias in chronic kidney disease work group of the national kidney foundation, kid¬ney disease outcomes quality initiative. Am J Transplant
2004;4:13-53.
31. Lentine KL, Brennan D. Statin use after renal transplantation:
a systematic quality review of trial-based evidence. Nephrol
Dial Transplant 2004;19:2378-86.
32. Bradford RH, Shear CL, Chremos AN et al. Expanded clinical evaluation of lovastatin (EXCEL) study results I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 petients with moderate hypercholesterolemia. Arch In¬tern Med 1991;151;43-9.
33. Katznelson S, Wilkinson AH, Kobashigawa JA et al. The ef¬fect of pravastatin on acute rejection after kidney transplan¬tation- A pilot study. Transplantation 1996;61:1469-1474.
34. Cosio FG, Pesavento TE, Pelletier RP et al. Patient survival af¬ter renal transplantation III: The effects of statins. Am J Kid¬ney Dis 2002;40:638-643.
35. Prasad GV, Ahmed A, Nash MM, Zaltzman JS. Blood pressu¬re reduction with HMG-CoA reductase inhibitors in renal transplant recipients. Kidney Int 2003;63:360-364.
36. Prasad GV, Chiu R, Nash MM, Zalzman JS. Statin use and bo¬ne mineral density in renal transplant recipients. Am J transp¬lant 2003;3:1320-1321.
37. Prasad GV, Kim SJ, Huang M et al. Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (Statins). Am J Transplant 2004;4:1897-1903.
38. Tuncer M, Suleymanlar G, Ersoy FF, Yakupoglu G. Compari¬son of the effects of simvastatin and pravastatin on acute re¬jection episodes in renal transplant patients. Transplant Proc
2000;32:622-625.
39. Sudhop T, Lutjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation
2002;106;1943-1948.
40. Puthenparumpil JJ, Keough-Ryan T, Kiberd M, Lawen J, Ki-berd BA. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proceedings
2005;37:1033-1035.
41. Kohnle M, Pietruck F, Kribben A, Phillipp Th, Heemann U, Witzke O. Ezetimibe for the treatment of uncontrolled hyperc-holesterolemia in patients with high dose statin therapy after renal transplantation. Am J Transplant 2006;6:205-208.
42. Vergoulas G, Miserlis G, Slonaki F et al. Combined treatment of hypercholesterolemia of renal transplant allograft recipi¬ents with fluvastatin and gemfibrosil. Transpl Int 2000;13:S64-
S67.
43. Angeles C, Lane BP, Miller F, Nord EP. Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant re¬cipients: biopsy evidence of tubular toxicity. Am J Kidney Dis
2004;44:543-50.

Thank you for copying data from http://www.arastirmax.com